Carisma Therapeutics Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Brokerages

Carisma Therapeutics Inc. (NASDAQ:CARM) has received an average rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $0.90.

A number of analysts have weighed in on CARM shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Carisma Therapeutics in a research report on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $1.00 price objective on shares of Carisma Therapeutics in a research note on Friday, August 8th.

Insider Buying and Selling

In other Carisma Therapeutics news, insider Michael Klichinsky sold 119,347 shares of the company’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $0.26, for a total transaction of $31,030.22. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold a total of 541,329 shares of company stock worth $138,176 over the last quarter. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Carisma Therapeutics stock. Jane Street Group LLC bought a new stake in shares of Carisma Therapeutics Inc. (NASDAQ:CARM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 0.36% of Carisma Therapeutics at the end of the most recent reporting period. 44.27% of the stock is currently owned by institutional investors.

Carisma Therapeutics Stock Up 18.2%

Shares of NASDAQ:CARM opened at $0.06 on Thursday. The firm has a market cap of $2.47 million, a P/E ratio of 0.08 and a beta of 1.94. Carisma Therapeutics has a 12-month low of $0.03 and a 12-month high of $1.27. The business has a fifty day simple moving average of $0.11 and a 200 day simple moving average of $0.25.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings results on Wednesday, November 12th. The company reported $1.07 earnings per share for the quarter. The company had revenue of $45.25 million during the quarter. As a group, equities research analysts expect that Carisma Therapeutics will post -1.32 EPS for the current year.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.